CSL, Vifor

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

Published on 08/07/2025 at 18:09 | prnewswire.co.uk

Vifor International AG (CSL Vifor) Travere Therapeutics, Inc. Austria Belgium Czech Republic Denmark Finland France Germany Greece Ireland Italy Luxembourg Netherlands Norway Poland Portugal Russia Spain Sweden Switzerland United Kingdom Australia California Europe New Zealand Pennsylvania

View original content:https://www.prnewswire.co.uk/news-releases/csl-vifor-and-travere-therapeutics-announce-standard-eu-approval-for-filspari-in-iga-nephropathy-302439809.html

en | boerse | 67920699 |